As a point of clarification, the phrasing “Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon” is not really correct. The first (Russian) Dimebon study was not a Phase 3 trial. It was “Phase 2.” Upon retrospective review, the FDA determined that it met the critera for a pivotal trial for the Alzheimer’s indication. Results of that study are to be published in The Lancet in June or July 2008.
As a point of clarification, the phrasing “Medivat…
June 26, 2008